Jefferies keeps Buy on Zymeworks stock at USD 50 target

Published on 10/07/2026 at 03:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies kept Buy and a USD 50.00 target on September 29, 2026. Zymeworks stock stood at EUR 22.78 on October 5, 2026 versus EUR 22.78 prior close.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks Inc. (ISIN US98985Y1082) drew a Buy rating from Jefferies with a USD 50.00 price target in a report dated September 29, 2026, according to Markets Insider. The analyst view follows Zymeworks' September 28 update to its financial outlook after completing the Theravance Biopharma acquisition.

Guidance shifts toward recurring revenue

Zymeworks expects fiscal 2026 total revenue between USD 278.0 million and USD 292.0 million, while adjusted earnings before interest, taxes, depreciation and amortization are guided to USD 114.0 million-128.0 million. The ranges were disclosed in the September 28, 2026 release carried by Finanznachrichten. The metric is non-GAAP and reflects the enlarged business after the acquisition.

The transaction adds Zymeworks' 35.00 percent share of net U.S. profits from YUPELRI and royalties on sales outside the United States. In the first half of 2026, YUPELRI generated USD 133.1 million in sales and USD 38.4 million in collaboration revenue for Theravance, according to the same September 28 release.

Quarterly loss highlights execution risk

For the second quarter of 2026, revenue was USD 4.6 million, down from USD 48.7 million in the prior-year quarter, while the GAAP net loss was USD 45.0 million versus net income of USD 2.3 million. These figures were reported in the company's August 6, 2026 filing summarized by StockTitan.

The contrast explains the importance of the new revenue mix: collaboration and royalty cash flows must offset the volatility of milestone-driven periods while research spending continues. The company also used USD 49.3 million of its USD 125.0 million 2026 repurchase authorization by September 28, 2026, according to the guidance release.

Stock valuation and cash-flow scale

As of October 6, 2026, Zymeworks had a market capitalization of USD 1.9 billion. Its Nasdaq 52-week range was USD 16.00 to USD 31.34, placing the equity value between a prior low and high that frame the market's assessment of the acquisition and pipeline.

The Lang & Schwarz prior close for Zymeworks was EUR 22.78 on October 5, 2026. The next reported operating milestone is the company's fiscal third-quarter 2026 results, listed for November 10, 2026 by The Wall Street Journal. The further course of trading is shown by the continuously updated real-time quote of Zymeworks stock.